Somerset, NJ - April 21, 2015 – Catalent (Booth 1546), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the launch of ADVASEPT™ Lock, a stopper-less, glass- and needle-free vial for the safe and efficient delivery of injectable medications. Easily opened, ADVASEPT Lock attaches to a luer syringe, combining a safe, convenient and functional container closure with the security of an advanced aseptic filling solution.
Like the rest of Catalent’s advanced, aseptic ADVASEPT technology family, ADVASEPT Lock addresses many sterile manufacturing challenges by automating the container formation and filling of the drug product into a glass-free container closure, eliminating glass particulates and delamination issues, and drastically reducing the risk of foreign particle and microbial contamination. Minimizing the risk of these types of manufacturing issues has the potential to improve the reliability of supply that targets the root cause of many generic injectable drug shortage issues.
The technology also offers safety advantages, as no needle is required for the withdrawal of the vial contents, while the design avoids the risk of sharps injuries associated with the opening of traditional ampoules. Additionally, through efficient design of the manufacturing process, ADVASEPT Lock is a cost effective solution compared to traditional glass vials.
The ADVASEPT Lock technology is available in 1 ml, 3 ml and 5 ml container closures but may be custom designed to meet specific brand or delivery needs.For more information, visit Catalent at Interphex Booth 1546.
To arrange a meeting with Catalent at Interphex contact Ed Dutton at NEPR Edward@nepr.eu.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com